Company intelligence / Profile preview

云南龙津康佑生物医药

Kunming, Yunnan, China

Ownership: Private
Development stage: Other

Overview

Yunnan Longjin Kangyou Biological Medicine is a biotechnology company based in Kunming, China, operating as a specialized R&D subsidiary of Yunnan Longjin Pharmaceutical. The company focuses on the development of innovative biological drugs, particularly recombinant proteins and fusion proteins for metabolic and cardiovascular diseases. Its lead candidate, LY007, is a long-acting recombinant human GLP-1-Fc fusion protein currently in Phase 2 clinical trials for the treatment of type 2 diabetes. Longjin Kangyou represents the parent group's strategic shift toward high-tech biopharmaceutical innovation, leveraging modern molecular biology to address chronic health conditions.

Therapeutic areas: Endocrinology
Modalities: Recombinant fusion proteinBiologic
Industry: Biotech

Beyond the preview

Go deeper on 云南龙津康佑生物医药.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 云南龙津康佑生物医药.

Explore the full profile